Autophagy as a mechanism of Apo2L/TRAIL resistance

References

• Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271;1996:12687–12690.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–682.
   PubMed Web of Science ®Google Scholar
• Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 2010;29:4752–4765. doi:10.1038/onc.2010.221.
   PubMed Web of Science ®Google Scholar
• Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets. 2015;19:1171–1185. doi:10.1517/14728222.2015.1049838.
   PubMed Web of Science ®Google Scholar
• Bento CF, Renna M, Ghislat G, Puri C, Ashkenazi A, Vicinanza M, Menzies FM, Rubinsztein DC. Mammalian autophagy: how does it work?. Annu Rev Biochem. 2016;85:685–713. doi:10.1146/annurev-biochem-060815-014556.
   PubMed Web of Science ®Google Scholar
• Marino G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nature Rev Mol Cell Biol. 2014;15:81–94. doi:10.1038/nrm3735.
   PubMed Web of Science ®Google Scholar
• White E. Deconvoluting the context-dependent role for autophagy in cancer. Nature Rev Cancer. 2012;12:401–410. doi:10.1038/nrc3262.
   PubMed Web of Science ®Google Scholar
• Towers CG, Thorburn A. Therapeutic targeting of autophagy. EBioMedicine. 2016. doi: 10.1016/j.ebiom.2016.10.034.
   PubMed Web of Science ®Google Scholar
• Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell. 1999;4:563–571.
   PubMed Web of Science ®Google Scholar
• Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK, Shin HC, Sung YC, Oh BH. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity. 1999;11:253–261.
   PubMed Web of Science ®Google Scholar
• Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14;2003:337–348.
   PubMed Web of Science ®Google Scholar
• Pan G, O"Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111–113.
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity. 1997;7:821–830.
   PubMed Web of Science ®Google Scholar
• Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363–14367.
   PubMed Web of Science ®Google Scholar
• Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 1997;7:1003–1006.
   PubMed Web of Science ®Google Scholar
• Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabeele P, and Fiers W. Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett. 1997;410:96–106.
   PubMed Web of Science ®Google Scholar
• Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 1999;59:2770–2775.
   PubMed Web of Science ®Google Scholar
• Wu GS, Burns TF, McDonald ER, 3rd, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Gen. 1997;17:141–143. doi:10.1038/ng1097-141.
   PubMed Web of Science ®Google Scholar
• Morizot A, Merino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, Lanneau D, Bouyer F, Solary E, Chauffert B, et al. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Diff. 2011;18:700–711. doi:10.1038/cdd.2010.144.
   PubMed Web of Science ®Google Scholar
• Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006;26:7046–7055. doi:10.1128/MCB.00520-06.
   PubMed Web of Science ®Google Scholar
• Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nature Cell Biol. 2000;2:241–243. doi:10.1038/35008667.
   PubMed Web of Science ®Google Scholar
• Dickens LS, Boyd RS, Jukes-Jones R, Hughes MA, Robinson GL, Fairall L, Schwabe JW, Cain K, Macfarlane M. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell. 2012;47:291–305. doi:10.1016/j.molcel.2012.05.004.
   PubMed Web of Science ®Google Scholar
• Peter ME. 2000. The TRAIL DISCussion: it is FADD and caspase-8! Cell Death Diff. 7:759–760. doi:10.1038/sj.cdd.4400735.
   PubMed Web of Science ®Google Scholar
• Mohamed MS, Bishr MK, Almutairi FM, and Ali AG. Inhibitors of apoptosis: clinical implications in cancer. Apoptosis. 2017;22:1487–1509. doi:10.1007/s10495-017-1429-4.
   PubMed Web of Science ®Google Scholar
• Morel J, Audo R, Hahne M, and Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem. 2005;280:15709–15718. doi:10.1074/jbc.M414469200.
   PubMed Web of Science ®Google Scholar
• Tran SE, Holmstrom TH, Ahonen M, Kahari VM, and Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Bioll Chem. 2001;276:16484–16490. doi:10.1074/jbc.M010384200.
   PubMed Web of Science ®Google Scholar
• Grunert M, Gottschalk K, Kapahnke J, Gundisch S, Kieser A, and Jeremias I. The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-kappaB by TRAIL. Cell Death Dis. 2012;3:e414. doi:10.1038/cddis.2012.154.
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2005;280:40599–40608. doi:10.1074/jbc.M509560200.
   PubMed Web of Science ®Google Scholar
• Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S, Liu ZG. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol. 2000;20:6638–6645.
   PubMed Web of Science ®Google Scholar
• Finnberg NK, Gokare P, Navaraj A, Lang Kuhs KA, Cerniglia G, Yagita H, Takeda K, Motoyama N, El-Deiry WS. Agonists of the TRAIL death receptor DR5 sensitize intestinal stem cells to chemotherapy-induced cell death and trigger gastrointestinal toxicity. Cancer Res. 2016;76:700–712. doi:10.1158/0008-5472.CAN-15-2759.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clinic Oncol. 2010;28:2839–2846. doi:10.1200/JCO.2009.25.1991.
   PubMed Web of Science ®Google Scholar
• Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, Reese D, Wiezorek J, Blackhall F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clinic Oncol. 2010;28:1527–1533. doi:10.1200/JCO.2009.25.4847.
   PubMedGoogle Scholar
• Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein N, et al. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody. Clinic Cancer Res. 2017;23:2942–2950. doi:10.1158/1078-0432.CCR-16-1784.
   PubMed Web of Science ®Google Scholar
• Holland PM. 2014. Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev. 25:185–193. doi:10.1016/j.cytogfr.2013.12.009.
   PubMed Web of Science ®Google Scholar
• Lemke J, Von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Diff. 2014;21:1350–1364. doi:10.1038/cdd.2014.81.
   PubMed Web of Science ®Google Scholar
• Zhang L, Fang B. 2005. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 12:228–237. doi:10.1038/sj.cgt.7700792.
   PubMed Web of Science ®Google Scholar
• Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. 2013;32:1341–1350. doi:10.1038/onc.2012.164.
   PubMed Web of Science ®Google Scholar
• Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D, Emme D, Roder C, Kalthoff H, Wajant H. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene. 2006;25:7434–7439. doi:10.1038/sj.onc.1209719.
   PubMed Web of Science ®Google Scholar
• Boya P, Reggiori F, Codogno P. Emerging regulation and functions of autophagy. Nature Cell Biol. 2013;15:713–720. doi:10.1038/ncb2788.
   PubMed Web of Science ®Google Scholar
• Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for self-eating. Cell Death Diff. 2005;12(Suppl 2):1542–1552. doi:10.1038/sj.cdd.4401765.
   PubMed Web of Science ®Google Scholar
• Babcook MA, Sramkoski RM, Fujioka H, Daneshgari F, Almasan A, Shukla S, Nanavaty RR, Gupta S. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells. Cell Death Dis. 2014;5:e1536. doi:10.1038/cddis.2014.500.
   PubMed Web of Science ®Google Scholar
• Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Current Op Cell Biol. 2010;22:124–131. doi:10.1016/j.ceb.2009.11.014.
   PubMed Web of Science ®Google Scholar
• Sharma A, Singh K, Mazumder S, Hill BT, Kalaycio, M, Almasan A. BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells. Cell Death Dis. 2013;4:e628. doi:10.1038/cddis.2013.155.
   PubMed Web of Science ®Google Scholar
• Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy. 7;2011:279–296.
   PubMed Web of Science ®Google Scholar
• Youle RJ, Narendra DP. 2011. Mechanisms of mitophagy. Nature Rev Mol Cell Biol. 12:9–14. doi:10.1038/nrm3028.
   PubMed Web of Science ®Google Scholar
• Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nature Cell Biol. 2010;12:213–223. doi:10.1038/ncb2021.
   PubMed Web of Science ®Google Scholar
• Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006;10:51–64. doi:10.1016/j.ccr.2006.06.001.
   PubMed Web of Science ®Google Scholar
• Mathew R, Kongara S, B Beaudoin B, Karp CM, Bray K, Degenhardt K, Chen G, Jin S, White E. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007;21:1367–1381. doi:10.1101/gad.1545107.
   PubMed Web of Science ®Google Scholar
• Park Y-E, Hayashi YK, Bonne G, Arimura T, Noguchi S, Nonaka I, Nishino I. Autophagic degradation of nuclear components in mammalian cells. Autophagy. 2009;5:795–804.
   PubMed Web of Science ®Google Scholar
• Singh K, Matsuyama S, Drazba JA, Almasan A. Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy. 2012;8:236–251. doi:10.4161/auto.8.2.18600.
   PubMed Web of Science ®Google Scholar
• Viry E, Noman MZ, Arakelian T, Lequeux A, Chouaib S, Berchem G, Moussay E, Paggetti J, Janji B. Hijacker of the antitumor immune response: autophagy is showing its worst facet. Front Oncol. 2016;6:246. doi:10.3389/fonc.2016.00246.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40:280–293. doi:10.1016/j.molcel.2010.09.023.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nature Rev Cancer. 2005;5:726–734. doi:10.1038/nrc1692.
   PubMed Web of Science ®Google Scholar
• Jiang P, Mizushima N. Autophagy and human diseases. Cell Res. 2014;24:69–79. doi:10.1038/cr.2013.161.
   PubMed Web of Science ®Google Scholar
• Bucur O, Ray S, Bucur MC, Almasan A. APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. Front Biosci. 11;2006:1549–1568.
   PubMedGoogle Scholar
• Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res. 63;2003:4713–4723.
   PubMed Web of Science ®Google Scholar
• He W, Wang Q, Xu J, Xu X, Padilla MT, Ren G, Gou X, Lin Y. Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy. 2012;8:1811–1821. doi:10.4161/auto.22145.
   PubMed Web of Science ®Google Scholar
• Han J, Hou W, Goldstein LA, Stolz DB, Watkins SC, Rabinowich H. 2014. A complex between Atg7 and caspase-9: a novel mechanism of cross-regulation between autophagy and apoptosis. J Biol Chem. 289:6485–6497. doi:10.1074/jbc.M113.536854.
   PubMed Web of Science ®Google Scholar
• Niu TK, Cheng Y, Ren X, Yang JM. Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis. FEBS Lett. 2010;584:3519–3524. doi:10.1016/j.febslet.2010.07.018.
   PubMed Web of Science ®Google Scholar
• Lee JS, Li Q, Lee JY, Lee SH, JH Jeong JH, Lee HR, Chang H, Zhou FC, Gao SJ, Liang C, et al. FLIP-mediated autophagy regulation in cell death control. Nature Cell Biol. 2009;11:1355–1362. doi:10.1038/ncb1980.
   PubMed Web of Science ®Google Scholar
• You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C, Nguyen DM, Feun L. TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Mol Cell Biochem. 2013;374:181–190. doi:10.1007/s11010-012-1518-1.
   PubMed Web of Science ®Google Scholar
• Goodall ML, Fitzwalter BE, Zahedi S, Wu M, Rodriguez D, Mulcahy-Levy JM, Green DR, Morgan M, Cramer SD, Thorburn A. The autophagy machinery controls cell death switching between apoptosis and necroptosis. Dev Cell. 2016;37:337–349. doi:10.1016/j.devcel.2016.04.018.
   PubMed Web of Science ®Google Scholar
• Gump JM, Staskiewicz L, Morgan MJ, Bamberg A, Riches DW, Thorburn A. Autophagy variation within a cell population determines cell fate through selective degradation of Fap-1. Nature Cell Biol. 2014;16:47–54. doi:10.1038/ncb2886.
   PubMed Web of Science ®Google Scholar
• Han J, Hou W, Goldstein LA, Lu C, Stolz DB, Yin XM, Rabinowich H. Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem. 2008;283:19665–19677. doi:10.1074/jbc.M710169200.
   PubMed Web of Science ®Google Scholar
• Hou W, Han J, Lu C, Goldstein, LA, Rabinowich H. Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis. Autophagy. 2010;6:891–900. doi:10.4161/auto.6.7.13038.
   PubMed Web of Science ®Google Scholar
• Lv S, Wang X, Zhang N, Sun M, Qi W, Li Y, Yang Q. Autophagy facilitates the development of resistance to the tumor necrosis factor superfamily member TRAIL in breast cancer. Internat J Oncol. 2015;46:1286–1294. doi:10.3892/ijo.2014.2812.
   PubMed Web of Science ®Google Scholar
• Molenaar JJ, Gérard B, Chambon-Pautas C, Cavé H, Duval M, Vilmer E, Grandchamp B. Microsatellite instability and frameshift mutations in BAX and transforming growth factor-β RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. Blood. 1998;92:230–233.
   PubMed Web of Science ®Google Scholar
• Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Nat Acad Sci USA. 2000;97:10872–10877. doi:10.1073/pnas.190210897.
   PubMed Web of Science ®Google Scholar
• Singh K, Sharma A, Mir MC, Drazba JA, Heston WD, Magi-Galluzzi C, Hansel D, Rubin BP, Klein EA, Almasan A. Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin). Mol Cancer. 2014;13:70. doi:10.1186/1476-4598-13-70.
   PubMed Web of Science ®Google Scholar
• Ray S, Bucur O, Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis. 2005;10:1411–1418. doi:10.1007/s10495-005-2490-y.
   PubMed Web of Science ®Google Scholar
• Huang S, Okamoto K, Yu C, Sinicrope FA. p62/sequestosome-1 up-regulation promotes ABT-263-induced caspase-8 aggregation/activation on the autophagosome. J Biol Chem. 288;2013:33654–33666.
   PubMed Web of Science ®Google Scholar
• Di X, Zhang G, Zhang Y, Takeda K, Rivera Rosado LA, Zhang B. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget. 2013;4:1349–1364. doi:10.18632/oncotarget.1174.
   PubMedGoogle Scholar
• Knoll G, Bittner S, Kurz M, Jantsch J, Ehrenschwender M. 2016. Hypoxia regulates TRAIL sensitivity of colorectal cancer cells through mitochondrial autophagy. Oncotarget. 7:41488–41504. doi:10.18632/oncotarget.9206.
   PubMedGoogle Scholar
• Zarogoulidis P, Petanidis S, Domvri K, Kioseoglou E, Anestakis D, Freitag L, Zarogoulidis K, Hohenforst-Schmidt W, Eberhardt W. Autophagy inhibition upregulates CD4+ tumor infiltrating lymphocyte expression via miR-155 regulation and TRAIL activation. Molec Oncol. 2016;10:1516–1531. doi:10.1016/j.molonc.2016.08.005.
   PubMed Web of Science ®Google Scholar
• Siegelin MD, Dohi T, Raskett CM, Orlowski GM, Powers CM, Gilbert CA, Ross AH, Plescia J, Altieri DC. Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clinic Investig. 2011;121:1349–1360. doi:10.1172/JCI44855.
   PubMed Web of Science ®Google Scholar
• Moon JH, Jeong JK, Park SY. Deferoxamine inhibits TRAIL-mediated apoptosis via regulation of autophagy in human colon cancer cells. Oncol Rep. 2015;33:1171–1176. doi:10.3892/or.2014.3676.
   PubMed Web of Science ®Google Scholar
• Kim SW, Lee JH, Moon JH, Nazim UM, Lee YJ, Seol JW, Hur J, Eo SK, Lee JH, Park SY. Niacin alleviates TRAIL-mediated colon cancer cell death via autophagy flux activation. Oncotarget. 2016;7:4356–4368. doi:10.18632/oncotarget.5374.
   PubMedGoogle Scholar
• Nazim UM, Park SY. 2015. Genistein enhances TRAIL-induced cancer cell death via inactivation of autophagic flux. Oncol Rep. 34:2692–2698. doi:10.3892/or.2015.4247.
   PubMed Web of Science ®Google Scholar
• Xu J, Xu X, Shi S, Wang Q, Saxton B, He W, Gou X, Jang JH, Nyunoya T, Wang X, et al. Autophagy-mediated degradation of IAPs and c-FLIP(L) potentiates apoptosis induced by combination of TRAIL and Chal-24. J Cell Biochem. 2016;117:1136–1144. doi:10.1002/jcb.25397.
   PubMed Web of Science ®Google Scholar
• Nazim UM, Moon JH, Lee JH, Lee YJ, Seol JW, Eo SK, Lee JH, Park SY. Activation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL- induced apoptosis. Oncotarget. 2016;7:23468–23481. doi:10.18632/oncotarget.8048.
   PubMedGoogle Scholar